Scientists hunt for clues in blood cancer samples to improve future treatments

NCT ID NCT07154823

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 4 times

Summary

This study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal is to better understand these blood cancers and guide future therapy decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Avera Cancer Institue

    RECRUITING

    Sioux Falls, South Dakota, 57105, United States

    Contact Email: •••••@•••••

  • Cancer Care Associates of York

    RECRUITING

    York, Pennsylvania, 17403, United States

  • Cancer Care Specialists of Reno

    RECRUITING

    Reno, Nevada, 89511, United States

  • OhioHealth Research Institute

    RECRUITING

    Columbus, Ohio, 43214, United States

  • Taylor Cancer Research Center

    RECRUITING

    Maumee, Ohio, 43537, United States

  • The Center for Cancer and Blood Disorders

    RECRUITING

    Bethesda, Maryland, 20817, United States

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • University of Iowa Hospital and Clinics

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • Washington University in St. Louis

    RECRUITING

    St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.